Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD)

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 5, 2011, Pages 1235-1243

  Belibi, Franck ^a   Zafar, Iram ^a   Ravichandran, Kameswaran ^a   Segvic, Anamarija Bauer ^b   Jani, Alkesh ^a   Ljubanovic, Danica Galesic ^b   Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Electron microscopy

Indexed keywords

2 METHOXYESTRADIOL; BECLIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYST; ELECTRON MICROSCOPY; IMMUNOBLOTTING; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE CELL; LYSOSOME; MALE; MOUSE; MUTATION; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; WILD TYPE;

EID: 79955763565     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00348.2010     Document Type: Article

References (42)

1. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 293: C419-C428, 2007.
2. Belibi F, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs 19: 315-328, 2010.
3. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia- inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 29: 2570-2581, 2009.
4. Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong AC, Willam C, Gretz N, Eckardt KU. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 170: 830-842, 2007.
5. Bohensky J, Shapiro IM, Leshinsky S, Terkhorn SP, Adams CS, Srinivas V. HIF-1 regulation of chondrocyte apoptosis: induction of the autophagic pathway. Autophagy 3: 207-214, 2007.
6. Boya P, Gonzalex-polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25: 1025-1040, 2005.
7. Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res 17: 839-849, 2007.
8. Cowley, BD Jr, Rupp JC, Muessel MJ, Gattone VH. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 29: 265-272, 1997.
9. Dery MC, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37: 535-540, 2005.
10. Doctor RB, Serkova N, Hasebroock K, Zafar I, Edelstein CL. Distinct patterns of kidney and liver cyst growth in Pkd2WS25/- mice. Nephrol Dial Transplant 25: 3496-3504, 2010.
11. Ecder T, Fick-Brosnahan G, Schrier RW. Polycystic kidney disease. In: Diseases of the Kidney and Urinary Tract, edited by Schrier RW. Philadelphia, PA: Lippincott, Williams and Wilkins. 2007, p. 502-539.
12. Ecder T, Melnikov VY, Stanley M, Korular D, Lucia MS, Schrier RW, Edelstein CL. Caspases, Bcl-2 proteins and apoptosis in autosomaldominant polycystic kidney disease. Kidney Int 61: 1220-1230, 2002.
13. Edelstein CL. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle 4: e141-e145, 2005.
14. Edelstein CL. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 3: 1219-1226, 2008.
15. Hou X, Mrug M, Yoder BK, Lefkowitz EJ, Kremmidiotis G, D'Eustachio P, Beier DR, Guay-Woodford LM. Cystin, a novel ciliaassociated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 109: 533-540, 2002.
16. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002.
17. Issekutz AC, Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Int Immunopharmacol 8: 708-716, 2008.
18. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 584: 1287-1295, 2010.
19. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 9: 1004-1010, 2008.
20. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375, 2003.
21. Maiuri MC, Zalckvar E, Kimchi A, Kroemer A. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752, 2007.
22. Maxwell P. HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 14: 2712-2722, 2003.
23. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 140: 313-326, 2010.
24. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 6: 355-361, 2003.
25. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 8: 206, 2008.
26. Oh DJ, Dursun B, He Z, Lu L, Hoke TS, Ljubanovic D, Faubel S, Edelstein CL. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 294: F264-F271, 2008.
27. Plum SM, Park EJ, Strawn SJ, Moore EG, Sidor CF, Fogler WE. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BMC Musculoskelet Disord 10: 46, 2009.
28. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C.2-Methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10: 8665-8673, 2004.
29. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466-5471, 2006.
30. Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21: 489-497, 2010.
31. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystic-2 defective mice. Gastroenterology 138: 360-371, 2010.
32. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD). J Am Soc Nephrol 16: 46-51, 2005.
33. Tao Y, Kim J, Stanley M, He Z, Faubel SG, Schrier RW, Edelstein CL. Pathways of caspase-mediated apoptosis in autosomal dominant polycystic kidney disease (ADPKD). Kidney Int 67: 909-919, 2004.
34. Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease (PKD). Proc Natl Acad Sci USA 102: 6954-6959, 2005.
35. Tao Y, Zafar I, Falk S, Faubel S, He Z, Schrier RW, Edelstein CL. VEGF receptor (VEGFR) inhibition slows the progression of polycystic kidney disease (PKD). Kidney Int 72: 1358-1366, 2007.
36. Tao Y, Zafar I, Kim J, Schrier RW, Edelstein CL. Deletion of the caspase-3 gene markedly prolongs survival in the cpk mouse model of polycystic kidney disease (PKD). J Am Soc Nephrol 19: 749-755, 2007.
37. Tasdemir E, Galluzi LM, Chiara Maiuri M, Criollo A, Vitale I, Hangen E, Modjtahedi N, Kroemer G. Methods for assessing autophagy and autophagic cell death. In: Autophagosome and Phagosome, edited by Deretic V. Totowa, NJ: Humana, 2008, p. 29-76.
38. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177-188, 1998.
39. Wu G, Markowitz GS, Li L, D'Agati VD, Factor SM, Geng L, Tibara S, Tuchman J, Cai Y, Park JH, van Adelsberg J, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 24: 75-78, 2000.
40. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349-2353, 2009.
41. Zeier M, Jones E, Ritz E. Autosomal dominant polycystic kidney disease-the patient on renal replacement therapy. Nephrol Dial Transplant 11, Suppl 6: 18-20, 1996.
42. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. Mitochondrial autophagy is an HIF-1- dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892-10903, 2008.